

Clinical outcomes after total pancreatectomy: a prospective multicenter pan-European snapshot study

Anouk E.J. Latenstein MD¹, Lianne Scholten MD PhD¹, Hasan Ahmad Al-Saffar MD², Bergthor Björnsson MD PhD³, Giovanni Butturini MD PhD⁴, Giovanni Capretti MD⁵, Nikolaos A. Chatzizacharias MD PhD⁶, Chris Dervenis MD PhD FRCS⁷, Isabella Frigerio MD PhD⁴, Tom K. Gallagher MD FEBS FRCSI⁸, Silvia Gasteiger MD⁹, Asif Halimi MD², Knut J. Labori MD PhD¹⁰, Greta Montagnini MD¹¹, Luis Muñoz-Bellvis, MD PhD¹², Gennaro Nappo MD⁵, Andrej Nikov MD¹³, Elizabeth Pando MD¹⁴, Matteo de Pastena MD PhD¹¹, Jesús M. de la Peña-Moral MD PhD¹⁵, Dejan Radenkovic MD PhD¹⁶, Keith J. Roberts MD PhD FRCS⁶, Roberto Salvia MD PhD¹¹, Francisco Sanchez-Bueno MD PhD¹⁷, Chiara Scandavini MD², Mario Serradilla-Martin MD FACS¹⁸, Stefan Stättner MD^{9,19}, Ales Tomazic MD PhD²⁰, Martin Varga MD PhD²¹, Hana Zavrtanik MD²⁰, Alessandro Zerbi MD⁵, Mert Erkan MD²², Jörg Kleeff MD²³, Mickaël Lesurtel MD PhD²⁴, Marc G. Besselink MD PhD^{1*}, Jose M. Ramia-Angel MD PhD^{25*} for the Scientific and Research Committee of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA)

* Shared senior author

¹ Department of surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

² HPB-unit, Department of Upper GI diseases, Karolinska University Hospital, Stockholm, Sweden

³ Department of Surgery in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

⁴ Pancreatic Surgical Unit, Pederzoli Hospital, Peschiera del Garda, Verona, Italy

⁵ Pancreatic Surgery Unit, Humanitas Clinical and Research Center – IRCCS and Humanitas University Department of Biomedical Sciences, Rozzano, Pieve Emanuele, Milan, Italy

⁶ Department of HPB and Liver Transplant Surgery, Queen Elizabeth Hospital, University Hospitals of Birmingham NHS Trust, Birmingham, United Kingdom

⁷ Department of General Surgery, Medical School, University of Cyprus, Nicosia, Cyprus

⁸ Department of HPB and Transplant Surgery, St. Vincent's University Hospital, Dublin, Ireland

⁹ Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria

¹⁰ Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway

¹¹ General and Pancreatic Surgery Department, Pancreas Institute, University and Hospital Trust of Verona, Verona, Italy

¹² Department of Surgery, University of Salamanca/Hospital Universitario de Salamanca, Salamanca, Spain

¹³ Department of Surgery, Central Military Hospital Prague, Prague, Czech Republic

- ¹⁴ Department of Hepatopancreatobiliary and Transplant surgery, Hospital Vall d'Hebrón, Barcelona, Spain
- ¹⁵ Department of Pathology, Hospital Clínico Universitario “Virgen de la Arrixaca”, Murcia, Spain
- ¹⁶ Department of Digestive Surgery, Clinical center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- ¹⁷ Department of Surgery, Hospital Clínico Universitario “Virgen de la Arrixaca”, Murcia, Spain
- ¹⁸ ISS Aragón, Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
- ¹⁹ Department of Surgery, Salzkammergut Klinikum, Vöcklabruck, Austria
- ²⁰ Department of Abdominal Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia
- ²¹ Department of Surgery, Paracelsus Medical University, Salzburg, Austria
- ²² Department of Surgery, Koc University, Istanbul, Turkey.
- ²³ Department of Visceral, Vascular, and Endocrine Surgery, Martin Luther University, Halle-Wittenberg, Germany.
- ²⁴ Department of Digestive Surgery & Liver Transplantation, Croix Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France
- ²⁵ Department of General and Digestive Surgery, University Hospital of Guadalajara, Guadalajara, Spain.

Collaborators

M. Abu Hilal MD PhD (Department of Surgery, Southampton University Hospital, Southampton, United Kingdom), M. Bekheit MSc PhD FRCS (Department of Surgery, Aberdeen Royal Infirmary, Aberdeen, United Kingdom), C. Bertrand MD (Department of Surgery, CHU UCL Namur - Godinne, Yvoir, Belgium), A. Calvo MD PhD (Department of Surgery, Puerto Real University Hospital, Puerto Real, Spain), M. Garces-Albir MD PhD (Department of Surgery, Liver, Biliary and Pancreatic Unit, Hospital Clinico, University of Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain), O. Gingham MD PhD (Department of Surgical Oncology, Saint John Emergency Hospital, Bucharest, Romania), M.A. Gomez Bravo (Department of Hepato Biliary Pancreato and Transplant Surgery, Unversitary Virgen del Rocio Hospital, Sevilla, Spain), M. Jesus Castro MD (HPB Unit, Hospital Universitario Puerta del Mar, Cádiz, Spain), R. Jorba MD (Department of General and Digestive Surgery, Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain), D. Lopez Guerra PhD (Department of Hepatobiliary and Liver Transplant Surgery, Hospital Infanta Cristina, Badajoz Spain), N. Machairas MD PhD (3rd Department of Surgery, National and Kapodistrian University of Athens, Medical School, Athens, Greece), V.E. de Meijer MD PhD (Department of Surgery, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands), R. Miller MD (General Surgery Department, Kaplan Medical Center, Rehovot, Israel), I. Negoï MD PhD (Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania), V.B. Nieuwenhuijs MD PhD (Department of Surgery, Isala, Zwolle, the Netherlands), I. Passas

MD (Department of Surgical Oncology and HPB Surgery, Metropolitan Hospital, Athens, Greece), B. Pérez-Saborido MD PhD (Department of General and Digestive Surgery, Rio Hortega University Hospital, Valladolid, Spain), M. Prieto MD (Hepatobiliary surgery and liver transplant unit, Cruces university hospital, Bilbao, Spain), M. Rodriguez-Lopez MD PhD (Department of General and Digestive Surgery, Valladolid University Clinic Hospital, Valladolid, Spain), G. Roeyen MD PhD (Department of Hepatobiliary, Endocrine and Transplantation Surgery, Antwerp University Hospital, Antwerp, Belgium), J. Salinas MD PhD (Department of General and Digestive Surgery, Hospital Universitario la Paz, Madrid, Spain), A.L. Segreto MD (Department of General Surgery, Hospital SS Antonio, Biagio and Cesare Arrigo, Alessandria, Italy), I. Sideris (Department of Surgical Oncology and HPB Surgery, Metropolitan Hospital, Athens, Greece), M.A. Suárez-Muñoz MD PhD (General & Digestive Surgery Service, University Hospital Virgen de la Victoria, Málaga, Spain), A. Suhoor (Department of Surgery, Southampton University Hospital, Southampton, United Kingdom), F.J. Tejero-Pintor MD PhD (Department of General and Digestive Surgery, Rio Hortega University Hospital, Valladolid, Spain), C. Toso MD (Department of Surgery, Geneva University Hospitals, Geneva, Switzerland)

Corresponding author

Jose M Ramia-Angel, MD, PhD

HPB Surgical Unit, Department of Surgery, University Hospital of Guadalajara
Guadalajara 19002, Spain.

Tel: +34-915-336470 Fax: +34-949-209200

Mail: jose_ramia@hotmail.com (during review process: a.e.latenstein@amsterdamumc.nl)

Conflicts of interest: None

Running head: Clinical outcomes of total pancreatectomy

Authors' contribution:

Study design: AL, LS, ME, JK, ML, MB, JRA

Data acquisition: all co-authors

Manuscript writing: AL, LS, MB, JRA

Data analysis and interpretation: all co-authors

Manuscript revising: all co-authors

Final approval: all co-authors

Words: 2932 words

MINI ABSTRACT (46/50 words)

This prospective multicenter pan-European snapshot study (June 2018-June 2019) found a 25% major complication rate and a 90-day mortality of 8% in 277 patients undergoing total pancreatectomy in 43 centers. Annual volume <60 pancreatoduodenectomies, age, and estimated blood loss ≥ 2 L were independent predictors of in-hospital mortality.

ABSTRACT (245/250 words)

Objective: To assess outcomes among patients undergoing total pancreatectomy (TP) including predictors for complications and in-hospital mortality.

Background: Current studies on TP mostly originate from high-volume centers and span long time periods and therefore may not reflect daily practice.

Methods: This prospective pan-European snapshot study included patients who underwent elective (primary or completion) TP in 43 centers in 16 European countries (June 2018-June 2019). Subgroup analysis included cut-off values for annual volume of pancreatoduodenectomies (<60 vs. ≥ 60). Predictors for major complications and in-hospital mortality were assessed in multivariable logistic regression.

Results: In total, 277 patients underwent TP, mostly for malignant disease (73%). Major postoperative complications occurred in 70 patients (25%). Median hospital stay was 12 days (IQR 9-18) and 40 patients were readmitted (15%). In-hospital mortality was 5% and 90-day mortality 8%. In the subgroup analysis, in-hospital mortality was lower in patients operated in centers with ≥ 60 pancreatoduodenectomies compared <60 (4% vs. 10%, $p=0.046$). In multivariable analysis, annual volume <60 pancreatoduodenectomies (OR 3.78, 95%CI 1.18-12.16, $p=0.026$), age (OR 1.07, 95%CI 1.01-1.14, $p=0.046$), and estimated blood loss ≥ 2 L (OR 11.89, 95%CI 2.64-53.61, $p=0.001$) were associated with in-hospital mortality. ASA ≥ 3 (OR 2.87, 95%CI 1.56-5.26, $p=0.001$) and estimated blood loss ≥ 2 L (OR 3.52, 95%CI 1.25-9.90, $p=0.017$) were associated with major complications.

Conclusion: This pan-European prospective snapshot study found a 5% in-hospital after TP. The identified predictors for mortality, including low-volume centers, age, and increased blood loss, may be used to improve outcomes.

INTRODUCTION

Total pancreatectomy (TP) is mostly performed for diseases involving the entire pancreas, e.g. main duct intraductal papillary neoplasm (IPMN), chronic pancreatitis, or pancreatic cancer.¹⁻³ There is, however, a reluctance to perform TP, because of high postoperative mortality, and the resulting life-long endocrine and exocrine pancreatic insufficiency.^{4,5}

Current data on major morbidity and in-hospital mortality after TP are conflicting. A recent systematic review reported that overall morbidity ranged from 36% to 69% and mortality from 0% to 27%.⁶ In contrast, a study that only included patients from two high-volume centers reported a low 2.1% 30-day mortality after TP in the years 2000-2014.⁷ These study results are clearly heterogeneous and may not reflect current practice in recent years. Furthermore, the influence of center volume is unclear. This lack of data is inherent to the fact that TP is a relatively rare procedure. In order to properly inform patients, reliable and recent real-world data are required.

The relatively new snapshot study is a cross-sectional study design which enables an actual insight into current practice by collecting data in a short period of time in a large number of centers and therefore creates greater generalizability than randomized controlled trials or longitudinal studies.^{8,9} Snapshot studies are based on collaborative research and supported by the European-African Hepato-Pancreato-Biliary Association (E-AHPBA). The aim of this pan-European snapshot study was to assess short-term postoperative outcomes after elective TP.

METHODS

Patients and design

A prospective multicenter pan-European study was conducted according to the snapshot design. The aim was to collect a large dataset in a short time period using collaborative research and to create greater generalizability than single-center studies running over longer periods of time.^{8,9} All members of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA) were invited to participate. The participating centers included all consecutive patients who underwent elective TP for either malignant or non-malignant disease between June 1st 2018 until June 30th 2019. Patients undergoing elective primary TP, elective completion (after a previous partial pancreatic resection) TP, and in whom an intraoperative decision to extend the planned resection to TP were included. Patients who underwent TP in an emergency setting were excluded. This study is reported in accordance with the STROBE guidelines.¹⁰ The ethics committee of the University Hospital of Guadalajara, Spain waived the need for informed consent.

Data collection and definitions

Patient data were collected locally through an online electronic case report form in CASTOR (CIWIT B.V., Amsterdam). Baseline characteristics collected included sex, age, body mass index (BMI, kg/m²), previous abdominal surgery, comorbidity (pulmonary, cardiovascular, and gastrointestinal and hepatic), American Society of Anesthesiologists (ASA) physical

status, preoperative diabetes mellitus and neoadjuvant chemo(radio)therapy. Preoperative imaging was reviewed for tumor location and tumor involvement of vascular structures and other organs. Intraoperative outcomes were the type of surgery (open or minimally invasive), type of TP (elective primary, elective completion, intraoperative decision to perform TP), splenectomy, vein resection (portal vein or superior mesenteric vein), arterial resection (common or proper hepatic artery, accessory or aberrant hepatic artery, celiac trunk, or superior mesenteric artery), additional organ resection, estimated blood loss (including a categorical distribution in $<2L$ and $\geq 2L$), and operation time. Pathological outcomes were tumor origin, histology, resection margin, tumor differentiation, T-stage according to the 7th edition of AJCC TNM staging, and lymph node ratio.¹¹ Postoperative outcomes were collected up to 90 days postoperatively and during readmission when applicable. Collected outcomes included complications (i.e. general and pancreas specific complications), hospital stay (days), readmission, and mortality. Major postoperative complications were defined as a Clavien-Dindo (CD) score ≥ 3 .¹² Pancreatic surgery specific complications (only grade B and C) included delayed gastric emptying, post-pancreatectomy hemorrhage, and bile leakage and were defined by the International Study Group on Pancreatic Surgery (ISGPS).^{13–16} Mortality is presented as in-hospital and 90-day mortality. In-hospital mortality was defined as a patient who deceased during the initial hospital stay or, in case of earlier discharge, within 30 days after TP. Use of adjuvant chemotherapy was recorded. Data about endocrine and exocrine pancreatic insufficiency were collected at 3 and 6 months postoperatively. Annual center volume was based on the mean annual volume of pancreatoduodenectomies in 2018 and 2019. High or lower-volume centers were defined based on two previously used cut-off values, specifically <40 (lower-volume) or ≥ 40 (high-volume), or <60 (lower-volume) or ≥ 60 (very high-volume) pancreatoduodenectomies annually.^{17–19}

Systematic literature search

To compare our results to the current literature, PubMed was systemically searched for all published series which included at least 100 TPs, regardless of the study period and indication. Systematic reviews and studies with overlapping cohorts were excluded. Outcomes extracted per study included study period, study design, number of patients, indication, the percentages of complications, post-pancreatectomy hemorrhage, bile leakage, delayed gastric emptying, mortality, and long-term survival. Outcomes were compared to our study results.

Statistical analysis

Baseline characteristics are presented using descriptive statistics and compared using the Students t-test, Mann Whitney U test, or Chi-square test, as appropriate. Subgroup analysis were performed to assess the clinical outcomes in patients diagnosed with IPMN, in patients operated in very high-volume, high-volume, and lower-volume centers (cut-offs based on annual volume 60 and 40 pancreatoduodenectomies), and in patients with elective TP compared to patients with an intraoperative decision to perform TP. Predictors within patient characteristics, hospital volume, and intraoperative outcomes for major complications or in-hospital mortality were identified in univariable logistic regression models. Variables with a p-value <0.10 in univariable analyses were entered in the multivariable regression models

and backward step selection was used. The results are reported as odds ratio (OR) with corresponding 95% confidence interval (CI). All p-values were based on a 2-sided test and p-values of <0.05 were considered statistically significant. Data were analyzed using IBM SPSS Statistics for Windows version 26 (IBM Corp., Armonk, N.Y., USA).

RESULTS

During the 13-month study period, 277 patients who underwent TP were prospectively included from 43 centers in 16 European countries. The patients had a median age of 68 years (IQR 57-73) and 161 (58%) were male (Table 1). Preoperative diabetes mellitus was present in 101 patients (37%). During the study period, the median number of TPs per hospital was 3 (IQR 2-6) and the median annual number of pancreatoduodenectomies was 32 (IQR 17-78). An annual center volume of ≥ 40 pancreatoduodenectomies was reached in 18 centers, which performed a total of 217 TPs (78%) with a median of 7 TPs (IQR 5-15) per center. An annual center volume of ≥ 60 pancreatoduodenectomies was reached in 14 centers, which performed 193 TPs (70%) with a median of 8 TPs (IQR 5-23) per center (eFigure 1 , <http://links.lww.com/SLA/C678>).

Perioperative outcomes

Results on intraoperative, pathological, and postoperative outcomes are presented in Table 2, 3 and 4. TPs were performed by an open approach in 265 patients (96%). Neoadjuvant chemotherapy was given to 42 patients (15%). Vein resection was performed in 58 patients (21%) and arterial resection in 12 patients (4%), both mostly for malignant disease.

Major complications were reported in 70 patients (25%) and mostly consisted of CD grade 3 complications (n=40, 57%). A post-pancreatectomy hemorrhage occurred in 11 patients (4%), bile leakage in 17 patients (6%), and delayed gastric emptying in 20 patients (7%). Within 90 days after TP, 40 patients (15%) were readmitted of whom 15 patients (38%) had a complication with CD ≥ 3 . The median duration of readmission was 8 days (IQR 5-13). The in-hospital and 90-day mortality were 5% (n=15) and 8% (n=21), respectively. Causes of death of the 6 patients who died after initial hospital stay but within 90 days, were aspiration pneumonia accompanied by a diabetic ketoacidosis, complication of a second operation for acute arterial ischemia of the lower limb, sepsis with multi organ failure after start of chemotherapy, multi organ failure due to cardiac decompensation, portal vein and superior mesenteric vein thrombosis, and early recurrence of pancreatic cancer. At final pathological diagnosis, 202 patients (73%) had malignant disease. Among all patients with adenocarcinoma, 113 received any type of adjuvant chemo(radio)therapy (63%). Patients with a CD score ≥ 3 had a lower percentage of receiving adjuvant chemo(radio)therapy compared the other patients (40% vs. 72%, p<0.001).

At 3 months follow-up, 256 patients were alive and questions regarding endocrine and exocrine insufficiency were completed in 238 patients (data were missing in 18 patients). New-onset diabetes mellitus was present in 157 patients (66%), and preoperative diabetes had worsened in 42 patients (16%) and was unchanged in 39 patients (16%). Pancreatic enzyme replacement therapy was given to 230 patients (97%).

Subgroup analysis

In the 41 patients who underwent TP because of IPMN, major complications occurred in 7 patients (17%), and both in-hospital and 90-day mortality was 0% (Table 5). Patients in high-volume centers (≥ 40 pancreatoduodenectomies annually) had similar postoperative outcomes compared to lower-volume centers, except for hospital stay (12 days (IQR 8-17) vs. 14 days (11-21), $p=0.003$). In very high-volume centers (≥ 60 pancreatoduodenectomies annually) postoperative major complications were similar compared to lower-volume centers but in-hospital mortality was lower (4% vs. 10% in lower-volume centers, $p=0.046$), and 90-day mortality was 6% vs. 12%, respectively ($p=0.073$). There were no differences in outcomes between patients with elective primary TP compared to patients with an intraoperative decision to perform TP, except for diabetes related hypoglycemia during initial hospitalization or readmission (9% vs. 20%, respectively, $p=0.007$). The group of 17 patients who underwent elective completion TP was too small to take into account in this subgroup analysis.

Multivariable analyses

Based on the results in the subgroup analysis, hospital volume <60 or ≥ 60 was assessed within the multivariable analysis. Factors associated with major postoperative complications were $\text{ASA} \geq 3$ (OR 2.87, 95%CI 1.56-5.26, $p=0.001$), and estimated blood loss $\geq 2\text{L}$ (OR 3.52, 95%CI 1.25-9.90, $p=0.017$, eTable 1, <http://links.lww.com/SLA/C678>). In-hospital mortality was related to age (OR 1.07, 95% CI 1.01-1.14, $p=0.046$), estimated blood loss $\geq 2\text{L}$ (OR 11.89, 95%CI 2.64-53.61, $p=0.001$) and lower-volume centers (<60 pancreatoduodenectomies, OR 3.78, 95% CI 1.18-12.16, $p=0.026$, eTable 2). Vein or arterial resections were not associated with major postoperative outcomes and in-hospital mortality.

Systematic literature search

The systematic review retrieved 7 studies which included at least 100 TPs (Table 6). All studies were retrospective (including one post-hoc analysis of a prospective database). One study included series from two different countries. All studies had an inclusion period beyond 5 years. The number of included patients ranged from 100 to 813. Most studies included both malignant as non-malignant disease. The pancreatic specific complications post-pancreatectomy hemorrhage and bile leakage in our cohort were comparable to literature, but the rate of delayed gastric emptying rate in our study was lower. Mortality in our study was comparable with most published series, although one study had a lower 90-day mortality (3%), whereas one other study had a higher rate (11%).

DISCUSSION

This prospective multicenter pan-European snapshot study found a 5% in-hospital mortality after TP. The international snapshot approach allowed for inclusion of 277 patients from 16 countries in a relatively short period of only 13 months, hereby assuring data representative of current clinical practice. The multivariable analysis found an association between in-hospital mortality and annual center volume for pancreatoduodenectomy of <60 , age, and, estimated blood loss $\geq 2\text{L}$.

In this study, the decision to perform TP in patients with malignant disease was mostly made intraoperatively (e.g. in order to obtain a radical resection), thus striving for optimal survival outcomes.^{20,21} TP is also increasingly considered in patients with main-duct IPMN, which was associated with lower (0%) mortality.^{1,20} Generally, TP may be more often considered in recent years because of perceived improved surgical outcomes, increased use of surgery in patients with locally advanced pancreatic cancer, and better management of exocrine and endocrine insufficiency.^{7,22,23}

The present study found high rates of postoperative complications and 90-day mortality after TP. In the total cohort, causes for mortality were not only surgery-related but sometimes also disease-related (e.g. cancer recurrence). In an earlier series, postoperative complications were associated with a higher age and longer operation time, and there were no independent risk factors identified for mortality.⁷ In contrary, a large monocenter series demonstrated that perioperative mortality was related to high blood loss, longer operative time (≥ 7 hours) and arterial resection.²³ Independent predictors for major complications in the current study were ASA score and estimated blood loss ≥ 2 L, and predictors for in-hospital mortality included center volume, age and estimated blood loss ≥ 2 L. These risk factors should be taken into account during patient selection and the decision to refer patients. We found no association with arterial or vein resections and outcome, which could be related to the low number of 12 patients with arterial resection and 58 patients with vein resection. Also, malignant disease was not related to worse outcomes. No differences were observed in morbidity and mortality between patients who underwent elective primary TP or in whom it was intraoperatively decided to perform TP. An intraoperative decision to perform a TP is therefore feasible. However, because morbidity and mortality after TP are high, this decision should be very well-considered and this option should be discussed with patients prior to surgery.

To place the current findings in perspective, a systematic literature search was performed. Compared to the included series, this present study stands out because of its prospective and international multicenter design and short inclusion period with a relatively high number of patients. Our findings are comparable to previous literature in terms of morbidity and mortality and thus outcomes of TP seem not to have substantially improved over the latter years. Mortality in three registry studies from the USA was similar to our findings (mortality 6-11%).²⁴⁻²⁶ Mortality in high-volume centers is lower than in our cohort.⁷ Studies from the world's highest volume centers are less useful for daily clinical practice. The association between outcome and volume was confirmed in our subgroup analyses which showed more favorable results in centers with an annual pancreatoduodenectomy volume of ≥ 60 . The rate of major complications did not differ between very high and lower-volume centers (cut-off ≥ 60), although mortality rates were lower in very high-volume centers. This could be explained by a lower failure to rescue rate (i.e. better treatment of patients with a major complications) in very high-volume centers as was already shown for pancreatoduodenectomy.^{27,28} These findings further support the concept of centralization of major pancreatic surgery.

Comparison of our results with patients after pancreatoduodenectomy in the Dutch and German audit, showed similar rates of post-pancreatectomy hemorrhage and lower rates of delayed gastric emptying. This may be surprising since post-pancreatectomy hemorrhage is related to postoperative pancreatic fistula, which by definition cannot occur after TP. In-hospital mortality after pancreatoduodenectomy was 4.3% and 3.9% in respectively the German and Dutch audit and thus lower than after TP, except for very high-volume centers.²⁹ Results after pancreatoduodenectomy within the Swedish registry showed a lower major complication (15.3%) and 90-day mortality (3.5%) as compared to the current study.³⁰ A systematic review comparing TP and pancreatoduodenectomy confirmed these suggestions and showed that TP had worse outcomes as compared to pancreatoduodenectomy.³¹

A recent systematic review concluded that treatment of endocrine and exocrine insufficiency after TP remains challenging.⁵ In our cohort, some data on endocrine and exocrine insufficiency were collected but due to the short follow-up an accurate reflection of treatment and burdens of endocrine and exocrine insufficiency could not yet be demonstrated. Regarding exocrine insufficiency after TP, some patients did not receive pancreatic enzyme supplementation, which should be improved. The impact of long-term endocrine, exocrine insufficiency, and quality of life will have to be assessed in a longer term follow-up study.

The findings of this study should be interpreted considering some limitations. First, since participation in this study was voluntary, some selection bias towards higher-volume centers may have occurred. This bias, if present, would only further strengthen our findings of a high 90-day mortality after TP. Second, in retrospect, some data could have been collected otherwise. TNM staging should have been scored according to the 8th edition. Third, registration bias cannot be excluded. Although all variables were defined in the online Castor system, the relatively low rate of delayed gastric emptying in our study could be related to registration bias. This could be improved by an external control, but this is obviously highly challenging in 43 centers and 16 countries, let alone the current strict privacy laws. Fourth, pancreatic surgery expertise was based on center volume of pancreatoduodenectomy, which is common in pancreatic surgery literature. The relationship between pancreatoduodenectomy and TP volume is, however, not constant and symmetrically predictable between centers. Moreover, expertise increases with other resections, such as left sided resections and enucleations, and is also depending on the capability of the intensive care unit and interventional radiology. It might be possible that expertise is underestimated based on only pancreatoduodenectomy.

The international multicenter snapshot design is one of the main strengths of the study and allowed for the inclusion of a large number of patients in a very short time period. Snapshot studies require effort from physicians and residents to register data, but also extensive study coordination to ensure complete data collection. Especially, prospective follow-up within a snapshot study complicates the ease and should be excluded from study protocols if possible. A better alternative would be to perform a second snapshot study within the same cohort with (long-term) follow-up. The large advantage of this novel design is the accurate reflection of current practice and these results add substantially to those from studies with a selected

cohort, such as randomized controlled trials or series from high-volume centers. The results from our study form a solid basis for discussion about how to improve outcomes after TP.

In conclusion, this pan-European prospective snapshot study found a 5% in-hospital mortality after TP across Europe. Several risk factors for mortality and major complications were identified which could be useful for patient selection and selective patient referral.

ACCEPTED

REFERENCES

1. Griffin JF, Poruk KE, Wolfgang CL. Is It Time to Expand the Role of Total Pancreatectomy for IPMN? *Dig Surg*. 2016;33(4):335-342. doi:10.1159/000445019
2. The European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. *Gut*. 2018;67(5):789-804. doi:10.1136/gutjnl-2018-316027
3. Andrén-Sandberg Å, Ansorge C, Yadav TD. Are There Indications for Total Pancreatectomy in 2016? *Dig Surg*. 2016;33(4):329-334. doi:10.1159/000445018
4. Scholten L, Latenstein AE, van Eijck CH, et al. Outcome including long-term quality of life after total pancreatectomy (PANORAMA): A nationwide cohort study. *Surgery*. 2019. doi:10.1016/j.hpb.2019.03.019
5. Scholten L, Stoop TF, Del Chiaro M, et al. Systematic review of functional outcome and quality of life after total pancreatectomy. *Br J Surg*. 2019;106(13):1735-1746. doi:10.1002/bjs.11296
6. Petrucciani N, Nigri G, Giannini G, et al. Total Pancreatectomy for Pancreatic Carcinoma: When, Why, and What Are the Outcomes? Results of a Systematic Review. *Pancreas*. 2020;49(2):175-180. doi:10.1097/MPA.0000000000001474
7. Pulvirenti A, Pea A, Rezaee N, et al. Perioperative outcomes and long-term quality of life after total pancreatectomy. *Br J Surg*. 2019. doi:10.1002/bjs.11185
8. Borstlap WAA, Deijen CL, den Dulk M, et al. Benchmarking recent national practice in rectal cancer treatment with landmark randomized controlled trials. *Color Dis*. 2017;19(6):O219-O231. doi:10.1111/codi.13644
9. Bhangu A, Kolia AG, Pinkney T, Hall NJ, Fitzgerald JE. Surgical research collaboratives in the UK. *Lancet*. 2013;382(9898):1091-1092. doi:10.1016/S0140-6736(13)62013-9
10. Elm E Von, Altman DG, Egger M, Pocock SJ, Gøtzsche C, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335(806). doi:10.2471/BLT.07.045120
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A (Eds. . *AJCC Cancer Staging Manual*. 7th ed. Springer; 2010.
12. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. *Ann Surg*. 2004;240(2):205-213. doi:10.1097/01.sla.0000133083.54934.ae
13. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery*. 2007;142(5):761-768. doi:10.1016/j.surg.2007.05.005
14. Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH)-An International Study Group of Pancreatic Surgery (ISGPS) definition. *Surgery*. 2007;142(1):20-25. doi:10.1016/j.surg.2007.02.001
15. Besselink MG, Rijssen LB Van, Bassi C, Dervenis C. Pancreas Definition and classification of chyle leak after pancreatic operation : A consensus statement by the International Study Group on Pancreatic Surgery. *Surgery*. 2017;161(2):365-372. doi:10.1016/j.surg.2016.06.058
16. Koch M, Garden OJ, Padbury R, et al. Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery. *Surgery*. 2011;149(5):680-688. doi:10.1016/j.surg.2010.12.002
17. van der Geest LGM, van Rijssen LB, Molenaar IQ, et al. Volume-outcome relationships in pancreatoduodenectomy for cancer. *Hpb*. 2016;18(4):317-324. doi:10.1016/j.hpb.2016.01.515
18. Schmidt CM, Turrini O, Parikh P, et al. Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: A single-institution

- experience. *Arch Surg*. 2010;145(7):634-640. doi:10.1001/archsurg.2010.118
19. Liu Z, Peneva IS, Evison F, et al. Ninety day mortality following pancreatoduodenectomy in England: has the optimum centre volume been identified? *Hpb*. 2018;20(11):1012-1020. doi:10.1016/j.hpb.2018.04.008
 20. Kulu Y, Schmied BM, Warner J, Muselli P, Büchler MW, Schmidt JS. Total pancreatectomy for pancreatic cancer: Indications and operative technique. *Hpb*. 2009;11(6):469-475. doi:10.1111/j.1477-2574.2009.00085.x
 21. Demir IE, Jäger C, Schlitter MM, et al. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. *Ann Surg*. 2017;268(6). doi:10.1097/SLA.0000000000002345
 22. Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: Evaluation of morbidity and long-term Survival. *Ann Surg*. 2009;250(2):282-287. doi:10.1097/SLA.0b013e3181ae9f93
 23. Hartwig W, Gluth A, Hinz U, et al. Total pancreatectomy for primary pancreatic neoplasms: Renaissance of an unpopular operation. *Ann Surg*. 2015;261(3):537-546. doi:10.1097/SLA.0000000000000791
 24. Nathan H, Wolfgang CL, Edil BH, et al. Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: A population-based perspective. *J Surg Oncol*. 2009;99(2):87-92. doi:10.1002/jso.21189
 25. Murphy MM, Knaus WJ, Ng SC, et al. Total pancreatectomy: A national study. *Hpb*. 2009;11(6):476-482. doi:10.1111/j.1477-2574.2009.00076.x
 26. Johnston WC, Hoen HM, Cassera MA, et al. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base. *Hpb*. 2016;18(1):21-28. doi:10.1016/j.hpb.2015.07.009
 27. Sánchez-Velázquez P, Muller X, Malleo G, et al. Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome Comparisons. *Ann Surg*. 2019;270(2):211-218. doi:10.1097/SLA.0000000000003223
 28. van Rijssen LB, Zwart MJ, van Dieren S, et al. Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. *Hpb*. 2018;20(8):759-767. doi:10.1016/j.hpb.2018.02.640
 29. Mackay TM, Wellner UF, van Rijssen LB, et al. Variation in pancreatoduodenectomy as delivered in two national audits. *Br J Surg*. 2019;106(6):747-755. doi:10.1002/bjs.11085
 30. Tingstedt B, Andersson B, Jönsson C, et al. First results from the Swedish National Pancreatic and Periapillary Cancer Registry. *HPB*. 2019;21(1):34-42. doi:10.1016/j.hpb.2018.06.1811
 31. Yang DJ, Xiong JJ, Liu XT, Li J, Siriwardena KMDL, Hu WM. Total pancreatectomy compared with pancreaticoduodenectomy: A systematic review and meta-analysis. *Cancer Manag Res*. 2019;11:3899-3908. doi:10.2147/CMAR.S195726

TABLES

Table 1. Patient characteristics

	All patients (n=277)
Male	161 (58%)
Age at operation, median (IQR), years	68 (57-73)
BMI, median (IQR), kg/m ²	24 (22-27)
Indication	
Adenocarcinoma	153 (55%)
IPMN	78 (28%)
Neuroendocrine tumor	9 (3%)
Chronic pancreatitis	14 (5%)
Mucinous cystic neoplasm	2 (0.7%)
Solid pseudopapillary neoplasm	2 (0.7%)
Other	18 (7%)
Missing	1
Previous abdominal surgery	150 (55%)
Missing	5
Comorbidity	
Cardiovascular	124 (45%)
Gastrointestinal and hepatic	47 (17%)
Pulmonary	31 (11%)
ASA score	
I	27 (10%)
II	160 (58%)
III	88 (32%)
IV	2 (1%)
Preoperative diabetes mellitus	101 (36%)
Insulin dependent	51 (50%)
Non-insulin dependent	42 (42%)
Unknown type	8 (8%)
Vascular contact on CT or MRI	72 (27%)
Missing	9
Additional organ involvement on CT or MRI	14 (5%)
Missing	9
Neoadjuvant therapy	42 (15%)
Chemotherapy	29 (69%)
Chemoradiotherapy	13 (31%)
Missing	1

Values are numbers with percentages within parentheses unless indicated otherwise.

ASA: American Society of Anesthesiologist; BMI: Body Mass Index; IPMN: intraductal papillary mucinous neoplasm.

Table 2. Intraoperative characteristics

	All patients (n=277)
Type of surgery	
Open surgery	266 (96%)
Minimally invasive surgery	11 (4%)
Type of TP	
Intraoperative decision to perform TP	132 (48%)
Elective primary	127 (46%)
Elective completion	18 (7%)
Splenectomy	214 (77%)
Vein resection	58 (21%)
End-to-end anastomosis	33 (57%)
Wedge	18 (31%)
Segment resection, end-to-end anastomosis with graft	7 (12%)
Missing	4
Arterial resection	12 (4%)
Common or proper hepatic artery	5 (42%)
Superior mesenteric artery	4 (33%)
Accessory hepatic artery	2 (17%)
Celiac trunk	1 (8%)
Additional organ resection	
Partial gastrectomy (beyond Whipple) ^a	16 (6%)
Colon segment resection	2 (1%)
Extended right hemicolectomy	4 (1%)
Other	13 (5%)
Estimated blood loss, median (IQR), L	0.4 (0.3-0.8)
<2L	228 (93%)
≥2L	17 (6%)
Missing	32
Operation time, median (IQR), minutes	405 (303-499)
Missing	4

Values are numbers with percentages within parentheses unless indicated otherwise.

TP: total pancreatectomy.

^a Subtotal gastrectomy or antrectomy

Table 3. Pathological outcomes

	All patients (n=277)
Origin	
Pancreas	241 (87%)
Ampulla of Vater	15 (5%)
Distal bile duct	6 (2%)
Duodenum	2 (1%)
Other ^a	13 (5%)
Malignant	202 (73%)
Histology	
Adenocarcinoma	183 (66%)
IPMN	41 (15%)
Neuroendocrine tumor grade 1 and 2	15 (5%)
Neuroendocrine tumor grade 3	-
Chronic pancreatitis	14 (5%)
Metastasis of renal cell carcinoma	10 (4%)
Mucinous cystic neoplasm	1 (0.4%)
Solid pseudopapillary neoplasm	1 (0.4%)
Serous cystadenoma	1 (0.4%)
Other	10 (4%)
IPMN ^b	
Mixed type	17 (6%)
Main duct	15 (5%)
Side branch	6 (2%)
Missing	3
Resection margin ^c	
R0	121 (60%)
R1	74 (37%)
R2	6 (3%)
Missing	1
Tumor differentiation ^d	
Well differentiated	16 (9%)
Moderately differentiated	89 (52%)
Poorly differentiated	62 (36%)
Undifferentiated	5 (3%)
Missing	11
T stage ^d	
T1	15 (9%)
T2	62 (39%)
T3	79 (49%)
T4	5 (3%)
Missing	22
Lymph node ratio ^d , median (IQR)	0.08 (0-0.19)

Values are numbers with percentages within parentheses unless indicated otherwise. TNM staging is according to tumor origin and based on the 7th edition of AJCC TNM staging TNM classification.

IPMN: intraductal papillary mucinous neoplasm.

^a Originating from kidney, stomach, vena cava inferior or gallbladder; ^b IPMN details are based on the preoperative CT or MRI; ^c Only in patients with malignant disease (n=202); ^d Only patients with adenocarcinoma (n=183).

Table 4. Postoperative outcomes

	All patients (n=277)
Patients with a major complication	70 (25%)
Clavien-Dindo grade 3	40 (57%)
Clavien-Dindo grade 4	15 (21%)
Clavien-Dindo grade 5	15 (21%)
Post-pancreatectomy hemorrhage	11 (4%)
Bile leakage	17 (6%)
Delayed gastric emptying	20 (7%)
Other complications	
Abdominal surgical site infection	37 (13%)
Diabetes related hypoglycemia	44 (16%)
Hospital stay ^a , median (IQR)	12 (9-18)
Readmission within 90 days	40 (15%)
<i>Missing</i>	2
In-hospital mortality	15 (5%)
90-day mortality	21 (8%)
Adjuvant chemo(radio)therapy ^b	113 (63%)
<i>Missing</i>	5
Diabetes mellitus ^c	238 (100%)
New-onset diabetes mellitus	157 (66%)
Unchanged diabetes mellitus	39 (16%)
Worsened diabetes mellitus	42 (18%)
Postoperative pancreatic enzyme replacement therapy for exocrine insufficiency ^c	230 (97%)

Values are numbers with percentages within parentheses unless indicated otherwise.

TNM staging is according to tumor origin and based on the 7th edition of AJCC TNM staging TNM classification.

^a Only calculated in patients who did not die during hospital admission (n= 262); ^b Only in patients with adenocarcinoma (n=183); ^c Data are only presented for patients with a completed 3 month follow-up for endocrine and exocrine insufficiency (n=238).

Table 5. Subgroup analysis

	Total cohort (n=277)	IPM N (n=41)	Center volume based on ≥40 pancreatoduodenectomies annually			Center volume based on ≥60 pancreatoduodenectomies annually			Type of total pancreatectomy		
			High- volume centers (n=217)	Lower - volume center s (n=60)	p- valu e	High- volume centers (n=193)	Lower - volume center s (n=84)	p- valu e	Electiv e primar y TP (n=127)	Intraoperativ e decision to perform TP (n=132)	p- valu e
Major complications	70 (25%)	7 (17%)	53 (25%)	17 (28%)	0.53 7	43 (22%)	27 (32%)	0.08 3	30 (24%)	35 (26%) 22 (63%)	0.59 1
Clavien-Dindo grade 3	40 (57%)	6 (67%)	33 (62%)	7 (41%)		27 (63%)	13 (48%)		15 (50%)	6 (17%) 7 (20%)	
Clavien-Dindo grade 4	15 (21%)	1 (22%)	9 (17%)	6 (35%)		9 (21%)	6 (22%)		7 (23%)	8 (27%)	
Clavien-Dindo grade 5	15 (21%)	-	11 (21%)	4 (24%)		7 (16%)	8 (30%)				
Post pancreatectomy hemorrhage	11 (4%)	1 (2%)	9 (4%)	2 (3%)	0.77 5	5 (3%)	6 (7%)	0.07 5	7 (6%)	3 (2%)	0.17 6
Bile leakage	17 (6%)	2 (5%)	13 (6%)	4 (7%)	0.84 7	9 (5%)	8 (10%)	0.12 1	9 (7%)	7 (5%)	0.55 1
Delayed gastric emptying	20 (7%)	3 (7%)	16 (7%)	4 (7%)	0.85 2	16 (8%)	4 (5%)	0.29 7	8 (6%)	10 (8%)	0.68 6
Other complications	37 (13%)	3 (7%)	30 (14%)	7 (12%)	0.66 4	28 (15%)	9 (11%)	0.39 4	16 (13%)	19 (14%) 27 (20%)	0.67 3
Abdominal surgical site infection	44 (16%)	9 (22%)	38 (18%)	6 (10%)	0.15 9	38 (20%)	6 (7%)	0.00 9	11 (9%)		0.00 7
Diabetes related hypoglycemia											
Readmission within 90 days	40 (15%)	7 (17%)	35 (16%)	5 (8%) 1	0.13 6	34 (18%)	6 (7%) 1	0.02 4	14 (11%)	21 (16%) 2	0.23 1
Missing	2		1			1					
Hospital stay ^a , days, median (IQR)	12 (9-18)	11 (9-14)	12 (8-17)	14 (11-21)	0.00 3	12 (9-17)	14 (10-21)	0.01 4	13 (10-17)	12 (9-19)	0.22 8
In-hospital mortality	15 (5%)	-	12 (6%)	3 (5%)	0.87 2	7 (4%)	8 (10%)	0.04 6	8 (6%)	6 (5%)	0.53 3
90-day mortality	21 (8%)	-	16 (7%)	5 (8%)	0.80 4	11 (6%)	10 (12%)	0.07 3	10 (8%)	10 (8%)	0.92 8

Values are numbers with percentages within parentheses unless indicated otherwise. ^a Only calculated in patients who did not die during hospital admission.

IPMN: intraductal papillary mucinous neoplasm; TP: total pancreatectomy.

Table 6. Comparison with published cohorts including at least 100 total pancreatectomies

Author	Inclusion period	Country	Monoc or multic enter	Retrospective or prospective	Patients, n	Indications for TP	Complications, n (%)	PPH, %	B L, %	DGE, %	Mortality, n (%)	Long-term survival
Reddy et al. ²²	1970 - 2007 37 years	Johns Hopkins Hospital, USA	Monocenter	Retrospective	100	Pancreatic adenocarcinoma	Surgical morbidity 69% CD $\geq$ 3 28%	14%	-	11%	30-day 8%	Median survival 13 months 5-year 19%
Nathan et al. ²⁴	1998 - 2004 6 years	USA	Multicenter (SEER)	Retrospective	376	Pancreatic adenocarcinoma	-	-	-	-	30-day 7% 90-day 11%	Median survival per location: Head 15 months Body/tail 12 months Unspecified 11 months
Murphy et al. ²⁵	1998 - 2006 8 years	USA	Multicenter (NIS)	Retrospective	4013 <i>Weighted (actual inclusion 813)</i>	Malignant and non-malignant	Major complications ^a 28%	4%	-	-	In-hospital 9%	-
Johnston et al. ²⁶	1998 - 2011 13 years	USA	Multicenter (NCDB)	Retrospective	5726	Pancreatic adenocarcinoma	-	-	-	-	30-day 6%	Median survival 15 months 5-year survival 12%
Hartwig et al. ²³	2001 - 2012 11 years	University of Heidelberg, Germany	Monocenter	Post hoc analysis of prospective database	434	Malignant and non-malignant	Nonsurgical morbidity 38% Surgical morbidity 37%	7%	6%	18%	30-day 5% In-hospital 12%	Median survival 24 months 5-year non-malignant

												t 94% 5-year adenocar cinoma 15%
Pulvi renti et al. ⁷	2001 - 2013 12 years	Johns Hopkin s Hospita l, and Univers ity of Verona (binatio nal)	Bicent er	Retrospe ctive	329	Malignan t and non- malignan t	Morbidity 59% CD≥3 23%	6 %	2 %	14 %	30- day 2% 90- day 3%	-
Schol ten et al. ⁴	2006 - 2016 10 years	The Netherl ands	Multic enter	Retrospe ctive	148	Malignan t and non- malignan t	CD≥3 32%	5 %	3 %	14 %	30- day 5% 90- day 8%	Median survival per diagnosis : IPMN 98 months PDAC 13 months
Curr ent stud y	2018 - 2019 1 year and 1 mont h	Pan- Europea n (intern ational)	Multic enter	Prospec tive	277	Malignan t and non- malignan t	CD≥3 25%	4 %	6 %	7%	In- hospit al 5% 90- day 8%	-

TP: total pancreatectomy; PPH: post pancreatectomy hemorrhage; BL: bile leakage; DGE: delayed gastric emptying; CD: Clavien-Dindo; IPMN: intraductal papillary mucinous neoplasm; PDAC: pancreatic ductal adenocarcinoma; NIS: Nationwide Inpatient Sample; SEER: Surveillance, Epidemiology, and End Results; NCDB: U.S. National cancer Database.

^a Major post-operative complications in this study were defined by specific diagnoses with codes based on their validation as true complications rather than comorbidities by the methods described by Lawthers et al.³²